VisMederi Holding
Improving human health
Vismederi Holding
Vismederi Holding is the company that holds a qualified share of the companies that are part of the VisMederi Group. The Group of Vismederi Holding operates in various business areas all related to Research and Innovation in the fields of Public Health, Life Sciences and Biotechnologies and is composed of VisMederi Srl, VisMederi Research Srl, VisMederi Life Sciences Srl, VisMederi Textyle Srl, VisMederi Pharma Srl, ETHS – Education and Training for Health Sciences Srl with single shareholder, Accurange Srl.
Revenues
Employees
Global Partnerships
Vismederi Holding: latest news
All the news of the group
Simone Paletti, Chief Financial Officer, speaker at the key finance forum in Milan organized by “Comunicazione Italiana”
VisMederi Group at the World Vaccine Congress in Washington, D.C.
VisMederi has achieved a distinguished place in the prestigious FT 1000 ranking by the Financial Times
VisMederi at the University of Siena’s prestigious event “USiena Game”
Our manuscript “#CEPI Centralized Laboratory Network: a qualification analysis” has been published in The Lancet Microbe Online
New Research Highlights the Importance of Vaccinations in Leukemia Patients
Making Strides in Global Health: VisMederi at the World Bio Summit 2023!
VisMederi reaffirms its position as a “Growth Leader”
GBA Roadshow 2023
Project Leader Silvia Grappi represented VisMederi at the 11th EDTCP meeting in Paris
Where we
are
The
founder
Emanuele Montomoli is Full Professor of Hygiene and Public Health at the University of Siena, Italy. He received his BSc and MSc in Life Sciences from the University of Siena, Italy in 1997 and he earned his MBiochem in 2001.
Partnership VisMederi / Shenzhen-Luohu district - MoU signing ceremony.
******
諒解備忘錄簽名儀式
#vismederigroup #vismederipartnership #vismederishenzen #signiningcerimony ... See MoreSee Less
0 CommentsComment on Facebook
Simone Paletti, Chief Financial Officer at VisMederi Group, recently attended a key finance forum in Milan organized by "Comunicazione Italiana".
This event served as a crucial meeting point for professionals in Corporate Finance, including Chief Financial Officers, Finance Directors, and Treasury Managers, to discuss strategies in the face of global uncertainties.
The forum's discussions centered on the vital role of CFOs in implementing business strategies, leading digital and organizational transformations, and integrating ESG objectives into their corporate plans. Paletti's participation reflects VisMederi's dedication to advancing in financial strategies and sustainability.
#VisMederiGroup #CorporateFinance #ESGStrategy #MilanFinanceForum2024
********
Simone Paletti, Chief Financial Officer del Gruppo VisMederi, ha partecipato giovedì 11 aprile a un importante forum di finanza a Milano, organizzato da "Comunicazione Italiana".
L'evento ha rappresentato un fondamentale punto di incontro per i professionisti del Corporate Finance, inclusi Chief Financial Officers, Direttori Finanziari e Responsabili della Tesoreria, per dibattere su come navigare l'incertezza globale.
Le discussioni hanno evidenziato il ruolo cruciale dei CFO nello sviluppo e nell'attuazione delle strategie aziendali, promuovendo trasformazioni digitali e organizzative e integrando gli obiettivi ESG nelle strategie d'impresa. La partecipazione di Paletti testimonia l'impegno del Gruppo VisMederi verso l'innovazione nelle strategie finanziarie e nella sostenibilità.
#VisMederi #FinanzaAziendale #StrategiaESG #ForumFinanzaMilano2024 #forumfinancial24 #integrability ... See MoreSee Less
0 CommentsComment on Facebook
Exciting news from our partners at Invivyd! They received emergency use authorization in the United States from the FDA for their investigational monoclonal antibody, aimed at the pre-exposure prophylaxis (prevention) of COVID-19 in certain authorized populations. A significant step forward in the fight against COVID-19, providing a new therapeutic option for those at risk.
Since 2020, VisMederi has been proud to collaborate with Invivyd. For this project VisMederi’s team has conducted escape mutation studies through serial passaging of authentic SARS-COV-2 variants in the presence of Invivyd’s antibodies. This critical work assesses the ability of Invivyd’s product candidates to resist viral escape, helping better characterize this innovative treatment. For more details on this important therapeutic option, read the full press release here: lnkd.in/eU53rF9W.
Together, we're making strides towards a safer, COVID-19 free world.
#Partnership #InnovationInHealthcare #COVID19Prevention #VisMederigroup #invivyd
*************
Novità importanti dai nostri partner di Invivyd! Hanno ricevuto l'autorizzazione all'uso di emergenza negli Stati Uniti dalla FDA per il loro anticorpo monoclonale sperimentale, mirato alla profilassi pre-esposizione (prevenzione) di COVID-19 in certe popolazioni autorizzate. Un passo significativo nella lotta contro il COVID-19, fornendo una nuova opzione terapeutica per coloro che sono a rischio.
Dal 2020, VisMederi è orgogliosa di collaborare con Invivyd.
Per maggiori dettagli su questa importante opzione terapeutica, leggi il comunicato stampa completo qui: lnkd.in/eU53rF9W.
Insieme, stiamo facendo passi avanti verso un mondo più sicuro, libero da COVID-19.
#Partnership #InnovazioneNellaSanità #PrevenzioneCOVID19 #VisMederi #Invivyd ... See MoreSee Less
0 CommentsComment on Facebook
VisMederi Group attended the World Vaccine Congress in Washington, D.C., acknowledged as the most significant and longstanding event dedicated to the field of vaccines. This congress served as an exceptional platform for engaging with leaders across the entire vaccine industry's value chain.
During the congress, our Chief Development Officer, Alessandro Manenti, delivered an insightful presentation on "Vaccine Evaluation: Serological Assays for Viruses and Respiratory Diseases," sharing valuable knowledge and the latest developments in the field.
We were proud to join forces with top professionals from around the world, initiating new collaborations and strengthening existing ones.
#VisMederi #vaccines #VaccineSaveLives #researchanddevelopment
°°°°°°
VisMederi Group ha partecipato al "World Vaccine Congress in Washington, D.C.", riconosciuto come l'evento più significativo e di lunga data dedicato al campo dei vaccini.
Durante il congresso, il Chief Development Officer, Alessandro Manenti, ha tenuto una presentazione su "Valutazione dei Vaccini: Assaggi Sierologici per Virus e Malattie Respiratorie," condividendo conoscenze preziose e gli ultimi sviluppi nel campo.
Un'opportunità per unire le forze con professionisti di spicco da tutto il mondo, avviando nuove collaborazioni e rafforzando quelle esistenti.
#VisMederiGroup #vaccini #ricerca #sviluppo ... See MoreSee Less
0 CommentsComment on Facebook